Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases

Overview

Journal BioDrugs

Specialties Allergy & Immunology
Genetics
Pharmacology

Date 2019 Feb 1

PMID 30701418

Citations 97

Authors

Anniina T Virtanen

Teemu Haikarainen

Juuli Raivola

Olli Silvennoinen

Affiliations

Soon will be listed here.

Abstract

Cytokines, many of which signal through the JAK-STAT (Janus kinase-Signal Transducers and Activators of Transcription) pathway, play a central role in the pathogenesis of inflammatory and autoimmune diseases. Currently three JAK inhibitors have been approved for clinical use in USA and/or Europe: tofacitinib for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, baricitinib for rheumatoid arthritis, and ruxolitinib for myeloproliferative neoplasms. The clinical JAK inhibitors target multiple JAKs at high potency and current research has focused on more selective JAK inhibitors, almost a dozen of which currently are being evaluated in clinical trials. In this narrative review, we summarize the status of the pan-JAK and selective JAK inhibitors approved or in clinical trials, and discuss the rationale for selective targeting of JAKs in inflammatory and autoimmune diseases.

Citing Articles

Safety of ilunocitinib tablets (Zenrelia™) after once daily oral administration in dogs.

Kuntz E, Gabor L, Toutain C BMC Vet Res. 2025; 21(1):144.

PMID: 40045302 PMC: 11881343. DOI: 10.1186/s12917-025-04579-1.

Understanding Cardiovascular Events With JAK Inhibitors: Tofacitinib Reduces Synovial and Vascular Inflammation but not the Prothrombotic Effects of Inflammatory Cytokines on Endothelium.

Zavoriti A, Miossec P ACR Open Rheumatol. 2025; 7(1):e11790.

PMID: 39800890 PMC: 11725533. DOI: 10.1002/acr2.11790.

Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis.

Mohammadi-Meyabadi R, Mallandrich M, Beirampour N, Garros N, Espinoza L, Sosa L Pharmaceutics. 2024; 16(10).

PMID: 39458616 PMC: 11510483. DOI: 10.3390/pharmaceutics16101287.

Differential type I and type III interferon expression profiles in rheumatoid and juvenile idiopathic arthritis.

Malik A, Slauenwhite D, McAlpine S, Hanly J, Marshall J, Derfalvi B Front Med (Lausanne). 2024; 11:1466397.

PMID: 39399119 PMC: 11468860. DOI: 10.3389/fmed.2024.1466397.

Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116.

Rzewinska A, Szlek J, Dabrowski D, Juszczyk E, Mroz K, Raikkonen H Pharmaceutics. 2024; 16(9).

PMID: 39339194 PMC: 11435004. DOI: 10.3390/pharmaceutics16091157.

References

Krueger J, Ferris L, Menter A, Wagner F, White A, Visvanathan S . Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015; 136(1):116-124.e7. DOI: 10.1016/j.jaci.2015.01.018. View

Ritchlin C, Krueger J . New therapies for psoriasis and psoriatic arthritis. Curr Opin Rheumatol. 2016; 28(3):204-10. PMC: 5812682. DOI: 10.1097/BOR.0000000000000274. View

Cai Y, Fleming C, Yan J . New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012; 9(4):302-9. PMC: 4132586. DOI: 10.1038/cmi.2012.15. View

Lebwohl M, Kavanaugh A, Armstrong A, Van Voorhees A . US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Am J Clin Dermatol. 2016; 17(1):87-97. PMC: 4733141. DOI: 10.1007/s40257-015-0169-x. View

Lim C, Cao X . Structure, function, and regulation of STAT proteins. Mol Biosyst. 2007; 2(11):536-50. DOI: 10.1039/b606246f. View

Riggs J, Hanna R, Rajan B, Zerrouki K, Karnell J, Sagar D . Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018; 5(1):e000261. PMC: 5890856. DOI: 10.1136/lupus-2018-000261. View

Sohn S, Barrett K, Van Abbema A, Chang C, Kohli P, Kanda H . A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol. 2013; 191(5):2205-16. PMC: 3748334. DOI: 10.4049/jimmunol.1202859. View

Lebwohl M, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley R . Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014; 70(5):871-81.e1-30. DOI: 10.1016/j.jaad.2013.12.018. View

Banfield C, Scaramozza M, Zhang W, Kieras E, Page K, Fensome A . The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis. J Clin Pharmacol. 2017; 58(4):434-447. DOI: 10.1002/jcph.1046. View

10.

Gregoriou S, Papafragkaki D, Kontochristopoulos G, Rallis E, Kalogeromitros D, Rigopoulos D . Cytokines and other mediators in alopecia areata. Mediators Inflamm. 2010; 2010:928030. PMC: 2837895. DOI: 10.1155/2010/928030. View

11.

Laria A, Lurati A, Marrazza M, Mazzocchi D, Re K, Scarpellini M . The macrophages in rheumatic diseases. J Inflamm Res. 2016; 9:1-11. PMC: 4755472. DOI: 10.2147/JIR.S82320. View

12.

Bissonnette R, Luchi M, Fidelus-Gort R, Jackson S, Zhang H, Flores R . A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. J Dermatolog Treat. 2016; 27(4):332-8. DOI: 10.3109/09546634.2015.1115819. View

13.

Keystone E, Taylor P, Drescher E, Schlichting D, Beattie S, Berclaz P . Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2014; 74(2):333-40. PMC: 4316868. DOI: 10.1136/annrheumdis-2014-206478. View

14.

Takeuchi T, Tanaka Y, Iwasaki M, Ishikura H, Saeki S, Kaneko Y . Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2015; 75(6):1057-64. PMC: 4893099. DOI: 10.1136/annrheumdis-2015-208279. View

15.

Bouchekioua A, Scourzic L, De Wever O, Zhang Y, Cervera P, Aline-Fardin A . JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia. 2013; 28(2):338-48. DOI: 10.1038/leu.2013.157. View

16.

van Vollenhoven R, Fleischmann R, Cohen S, Lee E, Garcia Meijide J, Wagner S . Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012; 367(6):508-19. DOI: 10.1056/NEJMoa1112072. View

17.

Kremer J, Bloom B, Breedveld F, Coombs J, Fletcher M, Gruben D . The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009; 60(7):1895-905. DOI: 10.1002/art.24567. View

18.

Sands B, Sandborn W, Feagan B, Lichtenstein G, Zhang H, Strauss R . Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. J Crohns Colitis. 2018; 12(10):1158-1169. DOI: 10.1093/ecco-jcc/jjy085. View

19.

Korolkova O, Myers J, Pellom S, Wang L, MKoma A . Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides. Clin Med Insights Gastroenterol. 2015; 8:29-44. PMC: 4459555. DOI: 10.4137/CGast.S20612. View

20.

Howell M, Fitzsimons C, Smith P . JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease. Ann Allergy Asthma Immunol. 2018; 120(4):367-375. DOI: 10.1016/j.anai.2018.02.012. View